The aim of this study was to identify the best practices for the detection of Shiga toxin-producing Escherichia coli (STEC) in children with diarrheal illness treated at a tertiary care center, i.e., sorbitol-MacConkey (SMAC) agar culture, enzyme immunoassay (EIA) for Shiga toxin, or the simultaneous use of both methods. STEC was detected in 100 of 14,997 stool specimens submitted for enteric culture (0.7%), with 65 cases of E. coli O157. Among E. coli O157 isolates, 57 (88%) were identified by both SMAC agar culture and EIA, 6 (9%) by SMAC agar culture alone, and 2 (3%) by EIA alone. Of the 62 individuals with diarrheal hemolytic uremic syndrome (HUS) seen at our institution during the study period, 16 (26%) had STEC isolated from cultures at our institution and 15 (24%) had STEC isolated at other institutions. No STEC was recovered in 31 cases (50%). Of the HUS cases in which STEC was isolated, 28 (90%) were attributable to E. coli O157 and 3 (10%) were attributable to non-O157 STEC. Consistent with previous studies, we have determined that a subset of E. coli O157 infections will not be detected if an agar-based method is excluded from the enteric culture workup; this has both clinical and public health implications. The best practice would be concomitant use of an agar-based method and a Shiga toxin EIA, but a Shiga toxin EIA should not be considered to be an adequate stand-alone test for detection of E. coli O157 in clinical samples.
Shiga toxin-producing Escherichia coli (STEC) causes a spectrum of disease, with manifestations ranging from mild selflimited diarrhea to the life-threatening hemolytic uremic syndrome (HUS) (1-7). The incidence and severity of STEC infections are highest in children, with disproportionate numbers of HUS cases being reported for this group (7-10). E. coli O157:H7 is the serotype most often implicated in HUS worldwide (1,9,(11)(12)(13)(14)(15).In 2009, the US Centers for Disease Control and Prevention (CDC) published guidelines indicating that laboratories should simultaneously perform a selective and differential agar-based test to detect E. coli O157 and a test to detect Shiga toxins or Shiga toxin genes for all stool samples submitted for bacterial culture (16). These complementary methods are recommended because of the increasing recognition that non-O157:H7 STEC strains cause disease and the lack of evidence that STEC enzyme immunoassays (EIAs) are as good as or better than sorbitol-MacConkey (SMAC) agar screening for the detection of E. coli O157, which remains the most clinically actionable STEC serotype. Furthermore, some studies suggest that a toxin EIA is inferior to SMAC agar screening for detecting E. coli O157:H7 (14, 17-24).Infections with STEC are rare (FoodNet data suggest that approximately 4,000 cases of E. coli O157:H7 infections per year occur in the United States) (25) but, for the individuals infected, there are considerable benefits to making a timely diagnosis. Specifically, the earlier a microbiological diagnosis is attained, the better the clinical outc...